宜宾双眼皮手术手术多少钱(宜宾隆鼻恢复过程) (今日更新中)

SINGAPORE, Sept. 7 (Xinhua) -- Singapore scientists have found possible new ways to treat a type of aggressive breast cancer that is unresponsive to current forms of treatment, local broadcaster Channel NewsAsia reported on Wednesday.The team of scientists at the Genome Institute of Singapore ( GIS) and National University of Singapore (NUS), led by GIS senior group leader Qiang Yu, found that the enzyme EZH2 acts by inhibiting genes that stop the growth of tumors in the body.The insights could open the door to developing more effective treatment for fast spreading breast cancers, especially the estrogen receptor-negative breast cancer that is common all over the world.It was also found that through EZH2, cancer is promoted in the body by activating specific genes that impact breast cancer progression and cancer stem cell self-renewal.Yu said the new understanding on how EZH2 works as a cancer- causing gene in breast cancer has important therapeutic implication."The results suggest that small molecule drugs that block enzyme activity of EZH2 may not work for cancers caused by EZH2's activation genes," Yu said.Currently pharmaceutical companies have been developing drugs only to the block EZH2 enzyme activity so that tumor suppressers can perform their protective role in blocking cancer growth.Researchers said the next step would be to develop biomarkers to identify tumors with EZH2.This step would enable better treatment methods, with one of options being the development of therapies that shut down EZH2 completely and not just inhibit its enzymatic function.The findings have been published on the journal Molecular Cell.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, July 12 (Xinhua) -- U.S. videogame giant Electronic Arts Inc. (EA) on Tuesday said it has agreed to buy PopCap Games, a leading provider of casual games for digital platforms, in a deal to accelerate its digital transformation.EA said it will pay about 650 million U.S. dollars in cash and 100 million dollars in shares of EA common stock to acquire privately-held PopCap, the maker of blockbuster games including " Plants vs. Zombies," "Bejeweled" and "Zuma".In addition, PopCap's owners are entitled to receive as much as 550 million dollars in earn-outs if certain earnings targets are met through December 2013, according to EA, which is headquartered in Redwood City in the U.S. state of California.Logos of PopCap Games and Electronic Arts Inc."EA and PopCap are a compelling combination," John Riccitiello, EA's chief executive officer, said in a statement."PopCap's great studio talent and powerful IP add to EA's momentum and accelerate our drive towards a 1-billion-dollar digital business," he noted.PopCap is one of the largest providers of casual videogames for mobile phones, tablets, PCs and social network sites, with more than 150 million games installed and played worldwide on platforms such as Facebook, RenRen, Google, iPhone, iPad and Android.EA said the purchase of PopCap is expected to close in August this year, subject to customary closing conditions including regulatory approvals.

BEIJING, Sept. 6 (Xinhuanet) -- NASA will launch on Thursday twin lunar orbiters built to map the gravity of Earth's moon in unprecedented detail, media reported Tuesday.The twin lunar probes, Graili-A and Graili-B, will blast off from Florida's Cape Canaveral Air Force Station at 8:37 a.m. EDT and at 9:16 a.m. EDT respectively Thursday, according to NASA.The Grail twins will travel three to four months to get to the moon under a slower but more economical plan.Artist concept of GRAIL mission. Grail will fly twin spacecraft in tandem orbits around the moon for several months to measure its gravity field in unprecedented detail.The two spacecrafts will reach the moon around New Year's Day when they will begin to probe the moon's composition from the crust to the core, according to NASA.The data collected by the probes will be used to better understand the moon's evolution and formation, NASA scientists said.Researchers will also use the twin probes to pinpoint the best landing sites for future explorations.The mission, from start to finish, costs 496 million U.S. dollars. The two Grail probes will crash into the moon after its mission.

来源：资阳报